QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.07%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.07%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.07%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
QQQ   304.28 (+0.14%)
AAPL   122.94 (-0.11%)
MSFT   214.24 (-0.52%)
FB   281.85 (-1.97%)
GOOGL   1,821.84 (-0.17%)
AMZN   3,186.73 (-0.52%)
TSLA   593.38 (+4.32%)
NVDA   535.84 (-1.07%)
BABA   266.91 (+2.14%)
CGC   28.63 (+1.60%)
GE   10.60 (+1.63%)
MU   69.90 (+1.14%)
AMD   92.31 (-1.53%)
T   29.23 (+0.48%)
NIO   45.35 (-5.48%)
F   9.21 (+0.11%)
ACB   11.24 (+2.65%)
NFLX   497.52 (-1.16%)
BA   237.20 (+5.96%)
GILD   60.86 (-0.44%)
DIS   153.24 (-0.24%)
Log in
NASDAQ:VXRT

Vaxart Stock Forecast, Price & News

$7.72
+0.44 (+6.04 %)
(As of 12/3/2020 12:00 AM ET)
Add
Compare
Today's Range
$7.35
Now: $7.72
$7.75
50-Day Range
$3.50
MA: $5.74
$7.98
52-Week Range
$0.28
Now: $7.72
$17.49
Volume6.51 million shs
Average Volume16.83 million shs
Market Capitalization$845.10 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.11
Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines. Its products include Influenza, Norovirus and Respiratory Syncytial Virus. The company was founded in 2004 and is headquartered in South San Francisco, CA.
Vaxart logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.33 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:VXRT
Previous SymbolNASDAQ:NABI
CUSIPN/A
Phone(650) 550-3500
Employees16

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$9.86 million
Book Value$0.27 per share

Profitability

Net Income$-18,650,000.00
Net Margins-281.50%

Miscellaneous

Market Cap$845.10 million
Next Earnings Date3/18/2021 (Estimated)
OptionableNot Optionable
$7.72
+0.44 (+6.04 %)
(As of 12/3/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive VXRT News and Ratings via Email

Sign-up to receive the latest news and ratings for VXRT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Vaxart (NASDAQ:VXRT) Frequently Asked Questions

How has Vaxart's stock been impacted by Coronavirus (COVID-19)?

Vaxart's stock was trading at $2.07 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, VXRT stock has increased by 272.9% and is now trading at $7.72.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Vaxart?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Vaxart
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Vaxart?

Wall Street analysts have given Vaxart a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Vaxart wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Vaxart's next earnings date?

Vaxart is scheduled to release its next quarterly earnings announcement on Thursday, March 18th 2021.
View our earnings forecast for Vaxart
.

How were Vaxart's earnings last quarter?

Vaxart, Inc. (NASDAQ:VXRT) issued its earnings results on Thursday, November, 12th. The biotechnology company reported ($0.08) EPS for the quarter, topping the consensus estimate of ($0.09) by $0.01. Vaxart had a negative return on equity of 84.90% and a negative net margin of 281.50%.
View Vaxart's earnings history
.

When did Vaxart's stock split? How did Vaxart's stock split work?

Vaxart's stock reverse split on the morning of Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of Vaxart stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for VXRT?

2 analysts have issued 1-year price targets for Vaxart's shares. Their forecasts range from $17.00 to $22.00. On average, they expect Vaxart's stock price to reach $19.50 in the next year. This suggests a possible upside of 152.6% from the stock's current price.
View analysts' price targets for Vaxart
.

Are investors shorting Vaxart?

Vaxart saw a increase in short interest during the month of October. As of October 30th, there was short interest totaling 32,350,000 shares, an increase of 21.1% from the October 15th total of 26,720,000 shares. Based on an average trading volume of 17,000,000 shares, the days-to-cover ratio is presently 1.9 days.
View Vaxart's Short Interest
.

Who are some of Vaxart's key competitors?

What other stocks do shareholders of Vaxart own?

Who are Vaxart's key executives?

Vaxart's management team includes the following people:
  • Andrei Floroiu, Director, Chief Executive & Financial Officer
  • Sean N. Tucker, Chief Scientific Officer
  • Margaret A. Echerd, Chief Accounting Officer, VP & Controller
  • John M. Harland, VP-Financial Planning & Administration
  • Brant Biehn, Senior Vice President-Commercial Operations

What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Who are Vaxart's major shareholders?

Vaxart's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (3.90%), Arrowstreet Capital Limited Partnership (1.10%), State Street Corp (0.83%), Charles Schwab Investment Management Inc. (0.55%), Morgan Stanley (0.18%) and National Asset Management Inc. (0.17%). Company insiders that own Vaxart stock include Armistice Capital Master Fund, Armistice Capital, Llc, John P Richard, Michael J Finney, Sean Tucker, Todd C Davis and Wouter Latour.
View institutional ownership trends for Vaxart
.

Which major investors are selling Vaxart stock?

VXRT stock was sold by a variety of institutional investors in the last quarter, including Bank Julius Baer & Co. Ltd Zurich, and Cambridge Investment Research Advisors Inc.. Company insiders that have sold Vaxart company stock in the last year include Armistice Capital, Llc, Todd C Davis, and Wouter Latour.
View insider buying and selling activity for Vaxart
.

Which major investors are buying Vaxart stock?

VXRT stock was purchased by a variety of institutional investors in the last quarter, including Arrowstreet Capital Limited Partnership, BlackRock Inc., Charles Schwab Investment Management Inc., National Asset Management Inc., State Street Corp, Morgan Stanley, California Public Employees Retirement System, and WINTON GROUP Ltd. Company insiders that have bought Vaxart stock in the last two years include Armistice Capital Master Fund, John P Richard, Michael J Finney, Sean Tucker, and Wouter Latour.
View insider buying and selling activity for Vaxart
.

How do I buy shares of Vaxart?

Shares of VXRT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $7.72.

How big of a company is Vaxart?

Vaxart has a market capitalization of $845.10 million and generates $9.86 million in revenue each year. The biotechnology company earns $-18,650,000.00 in net income (profit) each year or ($0.86) on an earnings per share basis. Vaxart employs 16 workers across the globe.

What is Vaxart's official website?

The official website for Vaxart is www.vaxart.com.

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The biotechnology company can be reached via phone at (650) 550-3500 or via email at [email protected]

This page was last updated on 12/3/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.